ABSTRACT We developed a radioimmunoassay to quantitate material crossreacting immunochemically with human methylmalonyl-CoA mutase (methylmalonyl-CoA CoA-carbonylmutase, EC 5.4.99.2), and have applied this assay to extracts of fibroblasts from controls and from 32 patients with methylmalonic acidemia due to inherited deficiencies in mutase activity. Four The above data on fibroblasts from the mut complementation group establish the fact that the abnormalities in these lines result from mutations at the structural gene locus for mutase. The molecular bases for these mutations remains obscure, however, particularly for those cell lines in the muto subgroup. To provide additional insight on this question from a different experimental perspective, we have developed a radioimmunoassay (RIA) to quantitate the amount ofimmunochemically crossreacting mutase protein present in extracts ofnormal fibroblasts and of fibroblasts from the mut complementation group. We report here the results ofthese studies on 28 mut lines (21 muto, 7 mut-), 4 cbl mutant lines, and 4 normal lines.
Biochemical studies in cell-free extracts of fibroblasts from this group have shown that many of them contain no detectable mutase activity under any conditions of assay; this subgroup is designated mut0 (5, 6) . Several other mut lines, however, have residual mutase activity that can be detected when large amounts of AdoCbl (>500 times the normal Km) are added to the assay. These lines, called mut-, have been shown to contain mutase enzymes that have abnormally high Km values for AdoCbl (5, 6) . In addition, the mutase enzymes in most ofthese mut-mutants have reduced Vm. values when compared to control.
The above data on fibroblasts from the mut complementation group establish the fact that the abnormalities in these lines result from mutations at the structural gene locus for mutase. The molecular bases for these mutations remains obscure, however, particularly for those cell lines in the muto subgroup. To provide additional insight on this question from a different experimental perspective, we have developed a radioimmunoassay (RIA) to quantitate the amount ofimmunochemically crossreacting mutase protein present in extracts ofnormal fibroblasts and of fibroblasts from the mut complementation group. We report here the results ofthese studies on 28 mut lines (21 muto, 7 mut-), 4 cbl mutant lines, and 4 normal lines.
The methylmalonic acidemias are a group of genetically determined metabolic diseases resulting from deficiencies in the activity ofthe mitochondrial enzyme methylmalonyl-CoA mutase (2-methylmalonyl-CoA CoA-carbonylmutase, EC 5.4.99.2; called herein "mutase") (1) . Mutase catalyzes the isomerization of Lmethylmalonyl-CoA to succinyl-CoA and requires adenosylcobalamin (AdoCbl) as a cofactor. Mutase is important in the pathway by which odd-chain fatty acids, branched-chain amino acids, thymine, uracil, and cholesterol are metabolized.
Previous biochemical and genetic studies on skin fibroblasts from affected individuals have shown that two general bases for mutase deficiency exist (2). In fibroblasts from some patients, intracellular synthesis of AdoCbl from its precursor, hydroxocobalamin (vitamin B12), is defective, resulting in reduced mutase activity in vivo. In cell-free extracts offibroblasts from such patients, however, mutase activity is normal when assayed with excess added cofactor. These mutants in cobalamin (Cbl) metabolism have been divided into four groups (cbl A-D) by complementation analysis with polyethylene glycol-induced heterokaryons (3).
In fibroblasts from other patients, Cbl metabolism is normal, and it is the mutase apoenzyme itself which is defective (4). These cell lines form a single complementation group, mut.
MATERIALS AND METHODS
Cells and Cell Culture. Human skin fibroblasts were routinely maintained in 75 cm2 flasks in Eagle's minimal essential medium, supplemented with 10% (vol/vol) fetal calf serum as described (7) . Cells were harvested with 0.25% trypsin-EDTA (7) and were washed three times at 40C with 10 ml of 0.15 M NaCl/0.01 M potassium phosphate, pH 7.5. The cell pellets were stored frozen at -90'C until used. The group and subgroup designations of the mutant lines were determined by complementation analysis (3) and by direct assay of mutase activity (ref. 6 ; A. Hack, personal communication).
Preparation of Fibroblast Extracts. Each frozen cell pellet (containing the cells from one flask) was dispersed in 1 ml of0. 15 M NaCl/0.01 M potassium phosphate, pH 7.5, and sonicated in an ice bath with the microprobe of a Bronson sonicator for 5 sec at a setting of 2 (approximately 50 W). Sonication was repeated four times at 1-min intervals for each ofthe samples, and then they were centrifuged at 1700 X g for 15 min at 40C. The supernatant fluid was recovered and immediately used in the RIA. Purification and lodination of Human Mutase. Mutase was purified to homogeneity from human placenta as described (8 added to the ester, and the iodination was completed as described (9) . The iodinated protein was separated from unreacted "2I-labeled ester by gel filtration on a 2 X 90 cm column of Sephadex G-150 equilibrated and eluted with 0.25 M NaCl/ 0.01 M potassium phosphate, pH 7.5/2.5 mg ofporcine gelatin per ml (9) . This procedure resulted in the formation of 'WI-labeled mutase which had a specific activity of approximately 1 X 10' cpm per Ag of protein.
RIA. A chicken was immunized with purified human mutase, and antiserum was obtained as described (8) . The RIA used 0.7 ml containing 35 ,mol of potassium phosphate (pH 7.5), 150
,mol of NaCl, various amounts of purified unlabeled mutase or fibroblast extract, and 0. 1 ml ofserum consisting ofantiserum diluted with preimmune serum. This mixture was incubated for 24 hr on a shaking platform at 4°C. Then 12 ng of "MI-labeled mutase was added, and the mixture was incubated again for 24 hr on a shaking platform at 4°C. Subsequently, 0.3 ml of saturated ammonium sulfate (Tris-buffered, pH 8) was added to each assay. The samples were mixed, incubated for 10 min at 40C, and then centrifuged at 30,000 x g for 30 min. Aliquots of 0. 75 ml were removed from the supernatants, and their content of 125I was determined in a Beckman Gamma 8000 system at 45% efficiency. Each set ofassays contained controls in which no antiserum was added and others in which no unlabeled mutase or fibroblast extract was added. The final concentration of 30% ammonium sulfate resulted in the precipitation of 10-20% ofthe "2I-labeled mutase in the presence ofpreimmune serum.
A standard curve was constructed for each RIA with purified mutase (2-60 ng). The limit of detectability was 2 ng of added mutase. Each fibroblast line was assayed at least twice, replicate values agreeing within 10% in each case. Samples were initially screened by using 0.4 ml of the fibroblast extract in the RIA. For a number of lines, the crossreacting material (CRM) in this amount of extract exceeded the upper limits of linearity of the standard curve ofthe RIA (see Fig. 3 ). These samples were reassayed with smaller quantities of extract so that CRM was within the range of7.5-15.0 ng. Other lines containing small quantities (<2.4 ng/0.4 ml) of CRM were reassayed with extracts prepared from 3 times as many cells. If no increase in CRM was observed, the line was considered CRM negative.
Anion Exchange Chromatography. A normal cell line and mutant cell line 454 (two 75-cm2 flasks each) were grown and harvested. After a final wash with 10 ml of0. 02 M sodium phosphate (pH 7.0), the cells were suspended in 2 ml of this buffer and sonicated. Each extract was applied to a 0.7 x 3.0 cm column containing 0.5 ml of DEAE-cellulose (Whatman) equilibrated with the same buffer, and the columns were washed with 10 ml of the buffer. Then the protein was eluted with a linear gradient (total volume, 60 ml) from 0.02 M sodium phosphate (pH 7) to 0.4 M NaCl/0.02 M sodium phosphate, pH 7. Fractions of 0.6 ml were collected, and 0.4 ml of each fraction was assayed for CRM by the RIA. Human placenta was solubilized in 0.028 M sodium phosphate (pH 7.0) as described (8) and fractionated on DEAE-cellulose as described, except on a larger scale. Fractions were collected and assayed for mutase activity in the presence of 60 AM AdoCbl as decribed (8) and for CRM by RIA.
Protein Determination. Protein was determined as described (10) with bovine serum albumin as a standard.
Polyacrylamide Disc Gel Electrophoresis. Polyacrylamide disc gel electrophoresis and protein staining were as described (8) . Gels run simultaneously were cut into 2-mm slices, which were either assayed for '25I content or eluted (8) and assayed for mutase activity.
RESULTS
Purification and lodinatioti of Mutase. Fig. 1 shows the mobility of purified mutase and "2I-labeled mutase on polyacrylamide disc gel electrophoresis. A single peak of "I activity was observed which corresponded to the peak ofmutase activity and to the stained band in two parallel gels. In addition, when "MI-labeled mutase was applied to a G-150 Sephadex column and eluted, only a small quantity of bound radioactivity appeared in the void volume, whereas 90% of the bound "I was eluted as a single symmetrical peak at 1.25 times the void volume, the typical elution volume for mutase (11) (data not shown).
Radioimmunoassay. Studies (8) with the antiserum utilized here have shown that it was able to inhibit mutase enzyme activity. In order to determine its efficacy in precipitating the '25I-labeled mutase, the experiment shown in Fig. 2 was carried out. Increasing amounts ofantiserum precipitated increasing amounts of "2I-labeled mutase up to -95% of the added label. The amount of the antiserum required to precipitate 1 ,ug of the labeled protein (25 Al) was similar to that reported to be necessary Gel slices 12 lines and ranged from =3% to 40% ofcontrol in 9 others (Fig.  4) . Significantly, replicate assays in each of the nine mut0 lines with CRM differed by <10%. Moreover, selected mut-and muto lines were tested for CRM by an independent immunoassay involving inhibition of the precipitation of mutase activity by antiserum. The amounts of CRM detected were comparable to the quantities found by RIA (data not shown).
Line 454, the muto mutant with the. largest amount of CRM, was studied further by anion exchange chromatography (Fig.  5) . The elution profile of the CRM from the mutant line (Fig.  5C ) was essentially identical to that obtained for CRM from a control line (Fig. SB) and from human placenta (Fig. 5A) , suggesting that the mutant protein differed very little in total charge from normal mutase. DISCUSSION The RIA developed in the course of these studies has proved to be both specific and sensitive. The "2I-labeled human mutase produced by the Bolton-Hunter procedure comigrates with unlabeled mutase on polyacrylamide gel electrophoresis ( Fig. 1) and Sephadex chromatography. It interacts with antiserum raised against the purified human enzyme at approximately the same titer as the unlabeled enzyme, is precipitated by the antiserum to an extent exceeding 90% (Fig. 2) , and competes with the unlabeled enzyme for binding to the antibody. The RIA itself is linear over a range of 2-15 ng of added unlabeled antigen (Fig. 3) and detects a single peak of CRM (which coincides with the elution position of mutase activity) when applied to fractions from DEAE-cellulose column chromatography of crude placental or control fibroblast extracts (Fig. 5) .
The data in Table 1 and Fig. 4 on the quantity of CRM detected by this RIA in extracts of fibroblasts show the expected diversity both within and among the mutant groups tested. The range of values obtained for control lines is relatively small; mutants of the cbl mutant groups have amounts of CRM that are not different from that of control, as expected on the basis of their normal mutase activity in vitro (2) . fore. In B, 0.8 mg of protein was applied to the column, and 52% of the applied CRM was recovered in the column fractions; in C, 1.5 mg of protein was applied, and 60% of the CRM was recovered.
single base changes which lead to amino acid substitutions that affect the kinetic parameters of the enzyme. In six of the seven lines reported here, these changes result simultaneously in fewer enzyme molecules being present in the cell because of either lowered rates of synthesis or increased rates of degradation. In the other line, the synthesis and degradation rates appear not to be affected. Similar findings have been reported for fibroblasts from patients with cystathionine synthase deficiency, which contain residual enzyme activity and CRM for synthase (12) .
The amount ofCRM in the mut-lines does not correlate well with the residual catalytic activity, as measured by the Vm.
values obtained from Lineweaver-Burk plots by Willard and Rosenberg (6) and Willard (13) . (12) and 18 patients with hypoxanthine phosphoribosyltransferase deficiency (15, 16) . In the case of cystathionine synthase deficiency, immunologic heterogeneity similar to that already detailed was observed. Mutant fibroblasts with residual enzyme activity had variable amounts of CRM, whereas those without activity were subdivided into those with and those without detectable CRM (12) . Other studies have not uncovered the same extent ofdiversity in amounts ofCRM as these two reports have. For example, hemolysates from all 17 patients with complete hypoxanthine phosphoribosyltransferase deficiency had no detectable CRM (15, 16) . The one patient with significant residual enzyme activity was shown to be a KY, mutant and had detectable CRM (15, 16) . CRM was similarly absent in patients with complete deficiency ofmuscle phosphorylase (17) , sucrase/ isomaltase (18) , and purine nucleoside phosphorylase (19) , whereas three patients with total galactose-l-phosphate uridyltransferase deficiency had normal amounts of CRM in erythrocytes (20) . The small number of patients reported in most of these studies may account for the lack of heterogeneity observed, although other explanations will have to be sought if further work produces similar results.
